Articles related to Hematology

The FDA announced a trial hold after two participants with sickle cell disease (SCD) in the LentiGlobin gene therapy trials developed AML and MDS. According to bluebird bio, the manufacturer of LentiGlobin products, the company was unable to find any cancer cells in the patient’s bone marrow and has asked the FDA for permission to resume clinical trials.

In this Original Investigation from JAMA Oncology, the authors seek to discover the characteristics that define modern randomized clinical trials (RCTs) in oncology and whether they differ from characteristics of RCTs from the preceding decades, as concerns have emerged regarding the use of putative surrogate end points, such as progression-free survival (PFS) and marginal effect sizes.

The data, concluded in a report posted to the preprint server medRxiv, support prioritization of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine, as barely one-quarter of patients with cancer obtained protection (28% immune efficacy rate, including 13% in patients with blood cancers) against COVID-19 after one dose of the Pfizer/BioNTech vaccine.

According to a recent study published in Clinical Toxicology, the authors examined the makeup of 17 brands of OTC supplements in the US, purchased online, that were labeled to include banned and unapproved stimulants, including deterenol, a beta-agonist that has never been approved for use in the US and which the FDA banned from supplements in 2004.

In this podcast/article from KevinMD, the story of Dr. Hasan Gokal is examined, a Houston physician who was fired from his public health job and was subsequently faced with criminal charges for stealing a vial of the vaccine. His case was also brought to the Texas Medical Board. In a sea of regulations and protocols, were his actions well-intentioned and in the best interest of patient care and safety?

This article from Radiopaedia discusses inclusions, usage, assessment of treatment response, caveats, history, and etymology of the internationally recognized Deauville five-point scale (Deauville 5PS), which was proposed in an international workshop attended by hematologists and nuclear medicine specialists in Deauville, France in 2009.